CRNX EBITDA Growth
Crinetics Pharmaceuticals Inc · EBITDA Growth
CRNX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-38.87%period ending
CRNX TTM EBITDA YoY % (-202.66% → -38.87%)
Year-over-year change
High-resolution chart · PNG
CRNX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -38.8652% | |
| -51.4027% | |
| -56.0254% | |
| -52.1536% | |
| -42.6882% | |
| -38.7919% | |
| -38.5099% | |
| -39.0022% | |
| -40.4701% | |
| -34.3825% | |
| -30.9915% | |
| -33.2861% | |
| -35.6841% | |
| -47.143% | |
| -52.6523% | |
| -52.2186% | |
| -52.52% | |
| -49.6222% | |
| -44.2281% | |
| -44.9677% | |
| -37.5502% | |
| -30.5105% | |
| -39.7771% | |
| -45.7911% | |
| -63.9176% | |
| -91.5059% | |
| -93.9164% | |
| -115.2224% | |
| -146.2568% | |
| -165.635% | |
| -202.6605% |